It was announced that Paradigm, a healthcare technology company focused on improving access to clinical research for patients, has closed a $203MM funding round and acquired Rev1 portfolio company Deep Lens.
Deep Lens has been focused on rebuilding the clinical research ecosystem by creating a platform that enables equitable access to trials for all patients while enhancing trial efficiency and reducing the barriers to participation for healthcare providers. Their mission and demonstrated commitment have been significant to the clinical research ecosystem. Through patient identification solutions, they help accelerate oncology clinical trial enrollment by connecting trial sponsors to community oncology practices at scale.
Paradigm is building a technology-enabled clinical research ecosystem to make clinical trials a care option for all patients.
“Deep Lens’ team has built a platform that delivers incredible value to many stakeholders in the clinical research ecosystem. We take pride as one of the first strategic partners that supported their take on providing a groundbreaking approach to clinical trial recruitment.”
“We aligned with their founders’, Dave Billiter, Simon Arkell and T.J Bowen, vision to be all about the patients and their possibility to receive the therapies they want and deserve, it has been a pleasure to support the Deep Lens team ” said Wayne Embree, EVP of Investments & Venture Acceleration for Rev1 Ventures.
To learn more about the how Paradigm is rebuilding of the Clinical Research Ecosystem, read the full article here on the New York Times
Learn more about Deep Lens here.
